Gallbladder Cancer (GC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as adenocarcinomas (90%). Gallbladder cancer patients are frequently asymptomatic at presentation or describe vague symptoms such as abdominal pain, anorexia, indigestion, weakness, nausea or vomiting, loss of appetite, and weight loss, and can present with jaundice, which can easily be misdiagnosed as cholecystitis. Biliary obstruction by cancer causes jaundice, clay-coloured stools, cola-colored urine, and skin pruritus.
·
The incidence of Gallbladder cancer (GC)
ranges from 3 to 4 per 100,000 in the USA.
Thelansis’s “Gallbladder Cancer (GC)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Gallbladder
Cancer (GC) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Gallbladder Cancer (GC) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Gallbladder Cancer (GC) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment